<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754217</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10386</org_study_id>
    <nct_id>NCT04754217</nct_id>
  </id_info>
  <brief_title>Valved Graft PMCF Study</brief_title>
  <official_title>Valved Graft Post-Market Clinical Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of Valved Graft PMCF Study is to demonstrate the safety and effectiveness of&#xD;
      the Abbott Valved Grafts for their approved indications, to meet the PMCF requirements of the&#xD;
      EU MDD.&#xD;
&#xD;
      Device safety will be evaluated by comparing 5-year annualized rate of all-cause mortality in&#xD;
      subjects implanted with an Abbott Valved Graft during aortic valve and ascending aorta&#xD;
      replacement, to predefined clinical acceptance criteria based on the surgical literature.&#xD;
      Valved Graft device effectiveness will be evaluated based on durability by comparison of&#xD;
      annualized rate of surgical reintervention in the replaced valve, to predefined clinical&#xD;
      acceptance criteria based on the surgical literature.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The VG-PMCF has a multicenter, observational, two group design in which 260 implanted&#xD;
      subjects will be prospectively followed through 5 years after implant of an Abbott Valved&#xD;
      Graft device in 2 groups:&#xD;
&#xD;
      Group 1: VAVGJ (N=200), including implants of VAVGJ in native or prosthetic valves Group 2:&#xD;
      CAVGJ (N=60), including implants of CAVGJ in native (n=30 subjects) or prosthetic (n=30&#xD;
      subjects) valves&#xD;
&#xD;
      Study enrollment will occur at up to 30 global centers. The study will enroll patients&#xD;
      expected to be implanted with an Abbott Valved Graft who meet all other study eligibility&#xD;
      requirements.&#xD;
&#xD;
      Subjects will be followed for 5 years post-implant. Study visits or data collection will&#xD;
      occur at baseline, implant, discharge, and annually post-implant. In-office visits will occur&#xD;
      at 1-, 3- and 5-years post-implant, and telephone follow-up will occur at 2 years and 4 years&#xD;
      post-implant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Anticipated">September 2029</completion_date>
  <primary_completion_date type="Anticipated">July 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>annualized event rate of all-cause mortality</measure>
    <time_frame>5 Years</time_frame>
    <description>Primary Safety Endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>annualized event rate of reintervention</measure>
    <time_frame>5 Years</time_frame>
    <description>Primary Effectiveness Endpoint</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Ascending Aorta Abnormality</condition>
  <condition>Aortic Dissection</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>VAVGJ (N=200), including implants of VAVGJ in native or prosthetic valves.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>CAVGJ (N=60), including implants of CAVGJ in native (n=30 subjects) or prosthetic (n=30 subjects) valves</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implant of VAVGJ in native or prosthetic valve</intervention_name>
    <description>Replacement of the aortic valve and ascending aorta</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Aortic Root Replacement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implant of CAVGJ in native or prosthetic valve</intervention_name>
    <description>Replacement of the aortic valve and ascending aorta</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Aortic Root Replacement</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll male and female subjects who will be undergoing replacement of a&#xD;
        native or prosthetic aortic heart valve and ascending aorta.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  cardiac surgery including the implant of a VAVGJ or CAVGJ for native or prosthetic&#xD;
             valve replacement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  anticoagulation therapy intolerant&#xD;
&#xD;
          -  active endocarditis&#xD;
&#xD;
          -  anatomical or medical, surgical, psychological or social contraindications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paolo Amato</last_name>
    <phone>+39 335 61 40 573</phone>
    <email>paolo.amato@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karine Miquel</last_name>
    <phone>+32 479 60 01 07</phone>
    <email>karine.miquel@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik Floridsdorf</name>
      <address>
        <city>Vienna</city>
        <zip>1012</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Herz-und Diabetes Zentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawla II</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cardinal Stefan Wyszynski Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi</name>
      <address>
        <city>Łódź</city>
        <zip>92-213</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Root Replacement</keyword>
  <keyword>Ascending Aorta Replacement</keyword>
  <keyword>Valved Graft</keyword>
  <keyword>CAVGJ</keyword>
  <keyword>VAVGJ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm, Dissecting</mesh_term>
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

